Countering oxysterol-driven neurodegeneration: diosgenin as a privileged steroidal scaffold for novel Alzheimer’s disease therapeutics
Aging Pathobiology and Therapeutics · 25.06.2026 · 8 (2)
DOI: 10.31491/apt.2026.06.226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Pathobiology and Therapeutics, online erschienen am 30.06.2026. Verfasst von Sarvesh Sabarathinam.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder characterized by amyloid-β accumulation, tau pathology, oxidative stress, neuroinflammation, and lipid dysregulation. The limited success of single-target therapeutics has shifted attention toward multi-target phytotherapeutics with pleiotropic neuroprotective properties. Diosgenin, a steroidal sapogenin structurally related to cholesterol-derived oxysterols, has emerged as a promising candidate owing to its antioxidant, anti-inflammatory, and neurorestorative activities. This mini-review highlights diosgenin as a structural antagonist to 7-ketocholesterol (7-KC), emphasizing its ability to modulate oxidative stress, amyloidogenesis, neuronal survival, and membrane stability. Additionally, translational strategies including semi-synthetic modification and nanocarrier-mediated brain delivery are discussed as future therapeutic avenues for AD management. Keywords : Alzheimer’s disease, diosgenin, 7-ketocholesterol, neuroprotection, steroidal sapogenins
Zitieren
APA
Sabarathinam, S. (2026). Countering oxysterol-driven neurodegeneration: diosgenin as a privileged steroidal scaffold for novel Alzheimer’s disease therapeutics. Aging Pathobiology and Therapeutics, 8(2). https://doi.org/10.31491/apt.2026.06.226
Vancouver
Sabarathinam S. Countering oxysterol-driven neurodegeneration: diosgenin as a privileged steroidal scaffold for novel Alzheimer’s disease therapeutics. Aging Pathobiology and Therapeutics. 2026;8(2). doi:10.31491/apt.2026.06.226
BibTeX
@article{Sabarathinam2026,
author = {Sabarathinam, Sarvesh},
title = {Countering oxysterol-driven neurodegeneration: diosgenin as a privileged steroidal scaffold for novel Alzheimer’s disease therapeutics},
journal = {Aging Pathobiology and Therapeutics},
year = {2026},
volume = {8},
number = {2},
doi = {10.31491/apt.2026.06.226}
}
EUVIMED